-
Abstract Number: OC 58.4
Ibrutinib inhibits BMX-dependent endothelial VCAM-1 expression in vitro and pro-atherosclerotic endothelial activation and platelet adhesion in vivo
-
Abstract Number: PB0525
Icodextrin as anti- adherence molecule affects cancer cells attachment to the fibrin deposits on the peritoneum surface
-
Abstract Number: OC 65.4
Idarucizumab for Reversal of Dabigatran: Multicenter Real-World Experience
-
Abstract Number: VPB1165
IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy
-
Abstract Number: PB0337
Identification and characterisation of ANKRD26-related thrombocytopenia in patients from the GAPP cohort.
-
Abstract Number: VPB1251
Identification and evaluation of novel variants associated with platelet function disorders by NGS-based high-throughput sequencing
-
Abstract Number: PB1029
Identification and functional characterisation of alternatively spliced novel isoforms of human protein C (PROC) gene
-
Abstract Number: PB1276
Identification of a red cell hemostatic mechanism causing COVID-19 microvascular obstruction
-
Abstract Number: OC 74.4
Identification of a site on Factor XII required for interactions with polyphosphate and other soluble polyanions
-
Abstract Number: OC 68.1
Identification of non-coding genomic regions involved in the aetiology of bleeding, platelet, and thrombotic disorders.
-
Abstract Number: PB0390
Identification of novel inhibitors of the platelet collagen receptor GPVI by a phenotypic screening assay
-
Abstract Number: OC 34.5
Identification of risk factors for major bleeding during anticoagulation and recurrent venous thromboembolism after its discontinuation in patients with a first unprovoked venous thromboembolism.
-
Abstract Number: VPB0437
Identifying Clinical Predictors for Thrombus Progression in Cirrhotic Patients with Untreated Splanchnic Vein Thrombosis
-
Abstract Number: OC 32.1
Identifying novel stabilin-2 plasma ligands using proximity labeling
-
Abstract Number: OC 23.5
Identifying phenotypes of deep vein thrombosis and their relation to clinical outcomes beyond recurrence
-
Abstract Number: OC 31.5
Identifying which emergency department patients should be tested for pulmonary embolism
-
Abstract Number: OC 43.1
Idntification of a von Willebrand factor homozygous deep intronic variant by next-generation analysis, and subsequent validation by mRNA analysis and study of the patient-derived endothelial cells
-
Abstract Number: VPB0610
IL-2 (T330G) gene promoter polymorphism and its effect on lymphocyte-platelet adhesion in patients with coronavirus infection SARS-COV-2 (COVID-19)
-
Abstract Number: OC 20.4
IL-6 is a Biomarker for Joint Bleeds in Hemophilia
-
Abstract Number: OC 04.5
Immune Medicated Thrombotic Thrombocytopenic Purpura relapse is associated with HLA-DRB1*15:01
-
Abstract Number: PB1053
Immunophenotyping and cell sorting of human MKs from human primary sources or differentiated in vitro from hematopoietic progenitors
-
Abstract Number: PB0309
Immunoprofiles and open ADAMTS13 in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura
-
Abstract Number: PB0660
Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: an ex-vivo study.
-
Abstract Number: PB0789
Impact of age on in vitro metabolism of clopidogrel: a potential explanation for high on-treatment platelet reactivity in elderly?
-
Abstract Number: VPB0939
Impact of Age-adjusted International Prognostic Index for Predicting Venous Thromboembolism in Thai Patients with Diffuse Large B-cell Lymphoma
-
Abstract Number: PB0987
Impact of amotosalen/UVA process for pathogen reduction in platelet concentrates on transfusion efficiency in cardiac surgery
-
Abstract Number: PB0381
Impact of Coagulation Factor XI (FXI) on the Binding of Platelet Glycoprotein Ibα to the von Willebrand Factor A1 Domain
-
Abstract Number: PB0092
Impact of COVID-19 pandemic on pulmonary embolism incidence and characteristics: a 24 months perspective
-
Abstract Number: PB1338
Impact of COVID-19 pandemic on VTE investigation and diagnosis rate in Belfast Health and Social Care Trust, Northern Ireland.
-
Abstract Number: PB1154
Impact of emicizumab on anticoagulant drugs at therapeutic concentrations using thrombin generation assay
-
Abstract Number: PB0544
Impact of fasting on INR in Ramadan on Muslim population taking warfarin.
-
Abstract Number: PB1010
Impact of fresh frozen plasma dosing in patients with a left ventricular assist device undergoing heart transplant
-
Abstract Number: VPB1374
Impact of implementation of primary thromboprophylaxis protocol in hospitalized hematologic malignancies patients.
-
Abstract Number: PB1172
Impact of inhibitors on the procoagulant efficacy of bypass agents or hemostatic factors in combination with emicizumab
-
Abstract Number: PB1288
Impact of periodontal inflammation on the cardiac tissues in a murine model
-
Abstract Number: PB0764
Impact of Puumala Hantavirus infection on primary haemostasis: potential mechanisms of thrombocytopenia
-
Abstract Number: PB0341
Impact of SARS-CoV-2 Vaccination in Thrombotic Thrombocytopenic Purpura Patients
-
Abstract Number: PB0081
Impact of the COVID-19 pandemic on anticoagulation control for patients using warfarin
-
Abstract Number: PB1062
Impact of the variability between normal pooled plasma batches on normalized ratio and mixing time reference cut-off values in lupus anticoagulant testing
-
Abstract Number: OC 60.2
Impact of thrombophilia testing on treatment decision and outcome of thromboembolism and pregnancy morbidity: a single center retrospective cohort study
-
Abstract Number: PB1404
Impact of Tissue factor promoter gene polymorphism with Recurrent pregnancy loss in India.
-
Abstract Number: PB0429
Impact of venous thromboembolism on physical functioning: Results from a prospective cohort study
-
Abstract Number: VPB0577
Impacts of antithrombotic agents on cellular physiology in the pancreatic tumoral environment
-
Abstract Number: PB0217
Impacts of Mim8 on routine coagulation assays, on intrinsic pathway coagulation factor assays and on thrombophilia coagulation tests
-
Abstract Number: PB0085
Impaired exercise capacity in Post-COVID syndrome: The role of VWF-ADAMTS13 axis
-
Abstract Number: PB0765
Impaired platelet function caused by Vibrio cholera outer membrane vesicles
-
Abstract Number: VPB0568
Implementation and scale-uping of Text Messages for primary care patients using Warfarin: a real life study
-
Abstract Number: PB1260
Importance of Erythrocyte Arginase-1 for Vascular Smooth Muscle Cell NO Signaling and Calcification
-
Abstract Number: OC 50.3
Improved Procoagulant Activity of Hemophilia B Causing Dysfunctional Factor IX Variants with Factor VIII Mimetics
-
Abstract Number: OC 11.3
Improved Survival in Severely Bleeding Trauma Patients Treated with Low-titer Group O Whole Blood Compared to Component Therapy
-
Abstract Number: PB0658
Improvement in school absence after factor replacement in students with haemophilia in Upper Assam, India
-
Abstract Number: PB1150
Improvement in the Musculoskeletal Health and Quality of Life-Outcomes among Patients with Severe Hemophilia A with Inhibitor after 2 years of Personalised Physiotherapy
-
Abstract Number: OC 01.2
Improvements in Health-Related Quality of Life in Adults with Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy
-
Abstract Number: PB0240
Improving Discussion of Menstrual Cycle and Bleeding During Well-Child Visits at a Pediatric Residency Clinic
-
Abstract Number: PB0231
Improving the provision of patient information regarding venous thromboembolism prevention at King’s College Hospital NHS Foundation Trust, London
-
Abstract Number: VPB0288
Improving Thromboprophylaxis in Children Admitted to a Quaternary Care Children’s Hospital with COVID-19
-
Abstract Number: PB0196
In silico structural analysis of FVIII molecular changes from missense pathogenic variants in non-severe hemophilia A patients displaying FVIII:C discrepancy between one-stage vs chromogenic assays
-
Abstract Number: PB0296
In vitro characterization of a novel Arg102 mutation in the metalloprotease domain of ADAMTS13
-
Abstract Number: VPB0571
In vitro effects of colloidal silica on clotting of plasma with or without coagulation factor deficiencies, heparization, lupus anticoagulant positivity, or high fibrinogen concentration.
-
Abstract Number: PB0829
In Vitro Field Study Assessing How Clinical Hemostasis Laboratories Analyze Recombinant and Plasma-Derived von Willebrand Factor Products
-
Abstract Number: PB0816
In vitro investigation of emicizumab efficacy and mode of action in vWD type 2 and 3 samples
-
Abstract Number: PB0163
In vitro monitoring of anti-coagulation therapy in whole blood using magnetic nanoparticles and susceptometry
-
Abstract Number: PB0717
In vitro Rescue of a Nonsense Mutation Responsible for Severe Coagulation Factor V Deficiency Using Ribosome Readthrough Agents
-
Abstract Number: PB0581
In vivo activation of the contact pathway by thrombin in sterile models of DIC in baboons
-
Abstract Number: OC 02.5
In vivo murine studies demonstrate that neutrophil activation by anti-NAP2 antibodies contributes to vaccine-induced immune thrombocytopenia and thrombosis (VITT)
-
Abstract Number: PB0358
In-depth analysis of the effects of unsteady flows on platelet release from suspensions of proplatelet-bearing megakaryocytes
-
Abstract Number: PB1105
In-vivo mimicking platelet thrombus formation in a microfluidic system (Anysis): Assessment of P2Y12 inhibitors for cardiology patients
-
Abstract Number: VPB0108
Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais
-
Abstract Number: PB1326
Incidence of Pregnancy-associated Venous Thromboembolism: Second Nationwide Study
-
Abstract Number: VPB0112
Incidence of thrombotic events in a population affected by Covid-19 in a general hospital in Veracruz, Mexico
-
Abstract Number: VPB0286
Incidence, Risk Factors, and Outcome of Thrombotic Events in Pediatric Cancer Patients
-
Abstract Number: PB0906
Incidences and Predictors of Venous Thromboembolism and Mortality in Patients Diagnosed with Lung Cancer among Saudi Population: Retrospective Two-Centre Cohort Study.
-
Abstract Number: PB0044
Increased blood viscosity and red blood cell aggregation in patients with COVID-19
-
Abstract Number: VPB0617
Increased CD62P Platelet Expression in Deceased COVID-19 Patients
-
Abstract Number: OC 66.4
Increased Endothelial Secretion and Reduced Circulatory Clearance Contribute to Elevated Plasma von Willebrand Factor Levels in Multiple Myeloma
-
Abstract Number: VPB0420
Increased expression of protein disulfide isomerase A1 on platelet surface in lupus anticoagulant-associated thrombosis
-
Abstract Number: PB0593
Increased Percentage of Extended Aα Chain Fibrinogen (αE) in COVID-19 Patients
-
Abstract Number: PB0857
Increased Platelet Activation and Platelet-Leukocyte Aggregate Formation in Primary Sclerosing Cholangitis
-
Abstract Number: PB1228
Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
-
Abstract Number: PB0383
Increased platelet procoagulant activity driven by fibrin-GPVI interaction alters clot structure
-
Abstract Number: OC 16.3
Increased Rate and Risk Factors of Venous Thromboembolism (VTE) in Older Patients (pts) with Melanoma Receiving Chemotherapy and/or Immune Checkpoint Inhibitors (ICI): a SEER-Medicare Analysis
-
Abstract Number: PB0035
Increased thrombus formation via procoagulant platelets in vaccine induced thrombotic thrombocytopenia (VITT)
-
Abstract Number: OC 27.3
Individualized target trough FVIII level and optimized prophylaxis in pediatric patients with hemophilia A
-
Abstract Number: OC 19.4
Induction of myeloid cell hypercoagulability is a maladaptive consequence of trained immunity
-
Abstract Number: PB0456
Inferior vena cava filter in a tertiary Hospital of Barcelona: a descriptive study of 185 cases.
-
Abstract Number: PB0590
Inflammatory convalescent plasma to treat COVID-19: impact of amotosalen/UVA Pathogen Reduction Technology
-
Abstract Number: PB0589
Inflammatory markers and auto-Abs to type I IFNs in COVID-19 Convalescent Plasma
-
Abstract Number: PB1269
Inflammatory stimuli reveal a differential glycocalyx response between venous and arterial endothelial cells
-
Abstract Number: PB0625
Influence of centrifugation and residual platelet count on PAI-1 plasma level, euglobulin clot lysis time and global fibrinolytic capacity of plasma
-
Abstract Number: PB0059
Influence of complement system genomic variations on the course of COVID-19
-
Abstract Number: PB1074
Influence of hemolysis, icterus and lipemia on Owren PT measured with a viscosity based detection coagulometer
-
Abstract Number: VPB1278
Influence of titanium dioxide particles on redox processes in human erythrocytes in vitro
-
Abstract Number: PB1240
Inherited Platelet Disorders Associated With Platelet Membrane Glycoproteins Abnormalities: A Portuguese Centre Experience
-
Abstract Number: PB1412
Inherited thrombophilia and non-O blood type associated with recurrent spontaneous abortion.
-
Abstract Number: PB0879
Inhibition of apoptosis during cold storage of platelet concentrates better maintains both platelet functionality and survival
-
Abstract Number: PB0346
Inhibition of PI3KC2alpha selectively reduces platelet recruitment after vascular injury while preserving thrombus architecture
-
Abstract Number: VPB0023
Inhibition of restenosis after orbital atherectomy of severely calcified artery using combined electrohydraulic low level shock wave therapy and 125I- mediated gamma-intravascular brachytherapy
-
Abstract Number: OC 77.1
Inhibition of the Class II PI 3-kinase, PI3KC2a, prevents thrombosis in hyperlipidaemic mice
-
Abstract Number: PB0376
Inhibition of the p75 pan neurotrophic receptor partly mitigates BDNF-induced platelet aggregation
-
Abstract Number: OC 22.2
Inhibition of von Willebrand factor through stabilization of the ristocetin-binding site
-
Abstract Number: PB0668
Inhibitor development is associated with decreased quality of life in patients with hemophilia
-
Abstract Number: PB0807
Inhibitors in 3 patients with type 3 von Willebrand disease in a Portuguese Centre – management of bleeding and surgeries
-
Abstract Number: PB0079
Inhibitory potential of anticoagulant and antiplatelet agents on COVID-19-induced NETs release
-
Abstract Number: OC 01.5
Innate and Adaptive Immune Responses to Adeno-Associated Viral Gene Therapy in the Severe Hemophilia A Dog Model
-
Abstract Number: OC 56.5
Insight into genetic predisposition to high plasma levels of Factor VIII (FVIII) and von Willebrand Factor (vWF) in a family with venous thrombosis.
-
Abstract Number: PB0413
Insights on Antiphospholipid antibody syndrome metabolomics by NMR
-
Abstract Number: PB0507
Insulin resistance links to procoagulant clot properties in young adult with type 1 diabetes: a cross-sectional observation study
-
Abstract Number: PB1248
Integrated diagnostic workflow in two siblings with albinism and suspected Hermansky-Pudlak syndrome
-
Abstract Number: OC 63.2
Inter-individual FVIII clearance heterogeneity in PWH in the iPATH study – biological determinants and clinical importance.
-
Abstract Number: PB1360
Inter-rater reliability of the UK Department of Health VTE risk assessment tool for medical and surgical hospital admissions
-
Abstract Number: PB0739
Interaction of Antiplatelet and Anticoagulant APAC with Complement Proteins Attenuates Complement Activation via C1q and Factor H
-
Abstract Number: PB0534
Interference of PLX038 (pegylated topoisomerase inhibitor SN-38) with coagulation assays
-
Abstract Number: PB0339
Interference with dendritic cells by siRNA-CD83 can reverse the polarization of Th1/Th2 and Treg/Th17 in ITP patients
-
Abstract Number: PB0143
Interferences in the dosage of D-dimer and variation between methodologies.
-
Abstract Number: PB1153
Interim Analysis from B-MORE, a 24-month Prospective, Multicentre, Non-interventional Study on Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B
-
Abstract Number: VPB0616
Interleukins that are mostly affected in severe coronavirus disease 2019 (COVID-19)
-
Abstract Number: LB 02.1
Intermediate versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow Study)
-
Abstract Number: PB1065
Interpretation of Coagulation Mixing Study Results in the Era of Direct Oral Anticoagulants
-
Abstract Number: PB1300
Intestinal Epithelial Protease-Activated Receptor-1 affects Gastrointestinal Motility and the Enteric Nervous System
-
Abstract Number: PB1137
Intracranial Haemorrhage in Children with Haemophilia in Turkey
-
Abstract Number: PB0980
Intravenous Ferric Gluconate Use in Anemic Heart Failure Patients at a Large Academic Medical Center
-
Abstract Number: OC 57.2
Inversed platelet/fibrin ratio in shear-dependent thrombus formation between patients with COVID-19 and sepsis identifies subtherapeutic GPIIb/IIIa blockade as a potential therapeutic target
-
Abstract Number: PB0090
Investigating Levels of Inflammatory Biomarkers Between SARS-CoV-2 Vaccinated and Unvaccinated Subjects
-
Abstract Number: OC 75.4
Investigating the health and function of murine platelets generated using a new ex-vivo lung system
-
Abstract Number: PB0540
Investigation of GGCX interaction with VKD proteins
-
Abstract Number: PB1280
Investigation of Podoplanin Signalling Complexes in Primary Lymphatic Endothelial Cells
-
Abstract Number: VPB0228
Investigation of properties of macropore silica sorbents and active dyes as ligands suitable for purification of factor VIII coagulation
-
Abstract Number: PB0533
Investigation of the epidemiology of inherited deficiency of coagulation factors in patients attending the Royal Hospital, Muscat, Oman
-
Abstract Number: PB1024
Investigation of thrombin generation assay to assess vaso-occlusive crisis in sickle cell disease
-
Abstract Number: PB0597
Investigation of thrombin generation in COVID-19 patients by a care setting design
-
Abstract Number: PB0529
Investigations of the impact of different bleeding disorders using a humanized in vivo mouse model
-
Abstract Number: OC 73.5
Investigations to assess Impact of Syk-inhibition on antibody-mediated desialylation: novel implications on therapy for immune thrombocytopenia
-
Abstract Number: PB0584
Involvement of The Contact Pathway in COVID-19 Coagulopathy
-
Abstract Number: VPB0394
iPSC-Derived Megakaryocytes as a Model to Study Human Platelet Integrin IIb3 Function
-
Abstract Number: PB1391
Iron deficiency in pregnancy is highly prevalent despite suboptimal screening: A population-based cohort study
-
Abstract Number: PO0019
Iron deficiency reduces mitochondrial respiration in skeletal muscle
-
Abstract Number: VPB0576
Is plasma-derived coagulation factor Xa safe for reversal of direct factor Xa inhibitor?
-
Abstract Number: PB1243
ITGB3/ITGA2B-related platelet disorders: phenotypic and genetic aspects of a series of 20 families evaluated in a single centre
-
Abstract Number: PB1198
ITP before and after COVID-19 vaccinations: a national cohort study
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.